These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 7777477)
21. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Gejman R; Swearingen B; Hedley-Whyte ET Hum Pathol; 2008 May; 39(5):758-66. PubMed ID: 18439942 [TBL] [Abstract][Full Text] [Related]
22. [Pituitary adenomas: relationship between invasiveness and proliferative cell nuclear index]. Tella Junior OI; Herculano MA; Delcelo R Arq Neuropsiquiatr; 2000 Dec; 58(4):1055-63. PubMed ID: 11105073 [TBL] [Abstract][Full Text] [Related]
23. [Expression of peroxisome proliferator-activated receptor-gamma in human pituitary adenomas and its correlation to tumor invasiveness]. Huang CX; Hou YH; Zhao JN; Wang YT; Li JJ; Wen L Ai Zheng; 2008 Jun; 27(6):590-4. PubMed ID: 18570731 [TBL] [Abstract][Full Text] [Related]
24. Expression of interleukin-6, interleukin-6 receptor (gp80), and the receptor's signal-transducing subunit (gp130) in human normal pituitary glands and pituitary adenomas. Kurotani R; Yasuda M; Oyama K; Egashira N; Sugaya M; Teramoto A; Osamura RY Mod Pathol; 2001 Aug; 14(8):791-7. PubMed ID: 11504839 [TBL] [Abstract][Full Text] [Related]
25. Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas. Liu W; Kunishio K; Matsumoto Y; Okada M; Nagao S J Clin Neurosci; 2005 Sep; 12(7):791-4. PubMed ID: 16198918 [TBL] [Abstract][Full Text] [Related]
26. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2. Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901 [TBL] [Abstract][Full Text] [Related]
27. p53, proliferating cell nuclear antigen, and Ki-67 expression in extrauterine leiomyosarcomas. O'Reilly PE; Raab SS; Niemann TH; Rodgers JR; Robinson RA Mod Pathol; 1997 Feb; 10(2):91-7. PubMed ID: 9127313 [TBL] [Abstract][Full Text] [Related]
28. Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Knosp E; Kitz K; Perneczky A Neurosurgery; 1989 Dec; 25(6):927-30. PubMed ID: 2601824 [TBL] [Abstract][Full Text] [Related]
29. Morphological evaluation of parathyroid adenomas and immunohistochemical analysis of PCNA and Ki-67 proliferation markers. Demıralay E; Altaca G; Demırhan B Turk Patoloji Derg; 2011; 27(3):215-20. PubMed ID: 21935871 [TBL] [Abstract][Full Text] [Related]
30. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53. Kasuki Jomori de Pinho L; Vieira Neto L; Armondi Wildemberg LE; Gasparetto EL; Marcondes J; de Almeida Nunes B; Takiya CM; Gadelha MR Neuroendocrinology; 2011; 94(1):39-48. PubMed ID: 21178332 [TBL] [Abstract][Full Text] [Related]
31. [Role of matrix metalloproteinases-9, 2 and their inhibitor-TIMP-1, 2 in invasive pituitary adenomas biological behavior]. He DS; Chen MZ; Wang HJ; Ke CL; Yan C; Zheng H; Hong YS Ai Zheng; 2002 Oct; 21(10):1124-8. PubMed ID: 12508658 [TBL] [Abstract][Full Text] [Related]
32. Proliferative activity in colonic adenomas as a predictor of metachronous adenomas as assessed by proliferating cell nuclear antigen immunohistochemistry. Paspatis GA; Karamanolis DG; Vasilakaki T; Zizi A; Xourgias V; Elemenoglou I; Hadziyannis SJ Am J Gastroenterol; 1995 Apr; 90(4):597-602. PubMed ID: 7717318 [TBL] [Abstract][Full Text] [Related]
33. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Trouillas J; Labat-Moleur F; Sturm N; Kujas M; Heymann MF; Figarella-Branger D; Patey M; Mazucca M; Decullier E; Vergès B; Chabre O; Calender A; Am J Surg Pathol; 2008 Apr; 32(4):534-43. PubMed ID: 18300794 [TBL] [Abstract][Full Text] [Related]
34. Analysis of the growth rate and cavernous sinus invasion of pituitary adenomas. Kawamoto H; Uozumi T; Kawamoto K; Arita K; Yano T; Hirohata T Acta Neurochir (Wien); 1995; 136(1-2):37-43. PubMed ID: 8748825 [TBL] [Abstract][Full Text] [Related]
35. [Immunohistochemistry expression of 3 markers (CEA, UEA-I and Ki-67) in nasal inverted papillomas]. De Gabory L; Deminière C; Stoll D Rev Laryngol Otol Rhinol (Bord); 2008; 129(3):159-65. PubMed ID: 19694158 [TBL] [Abstract][Full Text] [Related]
36. p53 protein, PCNA staining, and DNA content in follicular neoplasms of the thyroid gland. Czyz W; Joensuu H; Pylkkänen L; Klemi PJ J Pathol; 1994 Dec; 174(4):267-74. PubMed ID: 7884588 [TBL] [Abstract][Full Text] [Related]
37. Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. Hsu DW; Hakim F; Biller BM; de la Monte S; Zervas NT; Klibanski A; Hedley-Whyte ET J Neurosurg; 1993 May; 78(5):753-61. PubMed ID: 8096873 [TBL] [Abstract][Full Text] [Related]
38. Mdm2 and the p53 pathway in human pituitary adenomas. Suliman M; Royds J; Cullen D; Timperley W; Powell T; Battersby R; Jones TH Clin Endocrinol (Oxf); 2001 Mar; 54(3):317-25. PubMed ID: 11298083 [TBL] [Abstract][Full Text] [Related]
39. Correlation between SPARC (Osteonectin) expression with immunophenotypical and invasion characteristics of pituitary adenomas. Onoz M; Basaran R; Gucluer B; Isik N; Kaner T; Sav A; Elmaci I APMIS; 2015 Mar; 123(3):199-204. PubMed ID: 25556322 [TBL] [Abstract][Full Text] [Related]